<DOC>
	<DOCNO>NCT00860600</DOCNO>
	<brief_summary>This phase II multi-center , randomize , open-label study two parallel study group evaluate efficacy safety PG2 ITP patient .</brief_summary>
	<brief_title>Safety Efficacy Study PG2 Treat Idiopathic Thrombocytopenic Purpura ( ITP ) Patients</brief_title>
	<detailed_description>The primary objective exploratory study evaluate efficacy PG2 raise platelet count ITP patient use two dose schedule . The secondary objective determine safety PG2 treatment among patient .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Age 18 year old . 2 . Confirmed diagnosis chronic ITP , accord The American Society Hematology ( ASH ) Guidelines , least 6 month receive one prior conventional treatment ITP . 3 . Patient 's platelet count le 50,000 per cubic millimeter enrollment , platelet count calculate mean 2 platelet count take screening period day1 . 4 . The subject his/her legal delegate sign informed consent form . 5 . Absence condition , opinion investigator , could cause thrombocytopenia . 6 . If subject currently treat corticosteroid , treatment regimen/dose must stable ( ±25 % total dose/day ) minimum 4 week screen . However , subject must remain stable treatment regimen . If intent alter corticosteroid treatment regimen ( e.g. , taper corticosteroid ) Day 10 , subject may include study . 7 . If subject currently treat cyclophosphamide , azathioprine attenuate androgen , treatment regimen dose must stable ( ±25 % total dose/day ) minimum 3 month screen . However , intent alter treatment regimen Day 10 , subject may include study . 8 . If subject female childbearing potential , must negative result urinebased HCG pregnancy test . 9 . If subject childbearing potential , he/she must practice contraception use method proven reliability duration study . 1 . The subject history severe anaphylactic reaction blood bloodderived product , severe reaction IVIG IgG preparation . 2 . The subject know intolerant component investigational product . 3 . The subject receive live virus vaccine within last 3 month . 4 . The subject receive IVIG preparation within 1 month prior screen . 5 . The subject currently receive , receive , investigational agent within one month prior screen . 6 . The subject receive Rituximab within 3 month screen . 7 . The subject pregnant nursing . 8 . The subject diagnose HIV . 9 . The subject , screening , level great 2.5 time upper limit normal liver function alanine aminotransferase aspartate aminotransferase . 10 . The subject severe renal impairment ( define serum creatinine great 2 time upper limit normal BUN great 2.5 time upper limit normal range ) ; subject dialysis . 11 . The subject history deep vein thrombosis ( DVT ) thrombotic complication . 12 . The subject history hyperviscosity , transient ischemic attack ( TIA ) , stroke , thromboembolic event , unstable angina . 13 . The subject suffers acute chronic medical condition ( e.g. , renal disease predispose condition renal disease , coronary artery disease , protein lose enteropathy ) , opinion investigator , may interfere conduct study . 14 . The subject acquire medical condition , chronic lymphocytic leukemia , lymphoma , multiple myeloma , chronic recurrent neutropenia ( define absolute neutrophil count ( ANC ) &lt; 1 x 109/L ) diagnose nonITP patient . 15 . The subject unlikely adhere protocol requirement study likely uncooperative . 16 . The subject unwilling unable answer quality life questionnaires i.e . BFI . 17 . The subject undergone splenectomy within 4 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Idiopathic Thrombocytopenic Purpura ( ITP )</keyword>
	<keyword>Platelet Response</keyword>
	<keyword>PG2 Treatment</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Fatigue</keyword>
	<keyword>WHO Bleeding score</keyword>
</DOC>